PL2585469T3 - Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy - Google Patents
Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazyInfo
- Publication number
- PL2585469T3 PL2585469T3 PL11729889T PL11729889T PL2585469T3 PL 2585469 T3 PL2585469 T3 PL 2585469T3 PL 11729889 T PL11729889 T PL 11729889T PL 11729889 T PL11729889 T PL 11729889T PL 2585469 T3 PL2585469 T3 PL 2585469T3
- Authority
- PL
- Poland
- Prior art keywords
- benzodioxole
- heterocyclic compounds
- phosphodiesterase inhibitors
- benzodioxepine
- benzodioxepine heterocyclic
- Prior art date
Links
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 title 1
- -1 benzodioxepine heterocyclic compounds Chemical class 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35820910P | 2010-06-24 | 2010-06-24 | |
| EP11729889.3A EP2585469B1 (en) | 2010-06-24 | 2011-06-24 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2585469T3 true PL2585469T3 (pl) | 2017-07-31 |
Family
ID=44351701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11729889T PL2585469T3 (pl) | 2010-06-24 | 2011-06-24 | Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy |
| PL16020112T PL3070091T3 (pl) | 2010-06-24 | 2011-06-24 | Pochodne benzodioksolu jako inhibitory fosfodiesterazy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16020112T PL3070091T3 (pl) | 2010-06-24 | 2011-06-24 | Pochodne benzodioksolu jako inhibitory fosfodiesterazy |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8980905B2 (pl) |
| EP (2) | EP2585469B1 (pl) |
| JP (2) | JP6174997B2 (pl) |
| KR (1) | KR101864578B1 (pl) |
| CN (1) | CN102958937B (pl) |
| AU (1) | AU2011269429B2 (pl) |
| BR (1) | BR112012032813B1 (pl) |
| CA (1) | CA2802895C (pl) |
| CY (2) | CY1117862T1 (pl) |
| DK (2) | DK2585469T3 (pl) |
| ES (2) | ES2584055T3 (pl) |
| HR (2) | HRP20160919T1 (pl) |
| HU (2) | HUE044301T2 (pl) |
| IL (1) | IL223329A (pl) |
| LT (2) | LT3070091T (pl) |
| MX (1) | MX2012014131A (pl) |
| MY (1) | MY157481A (pl) |
| NZ (1) | NZ603895A (pl) |
| PL (2) | PL2585469T3 (pl) |
| PT (2) | PT2585469T (pl) |
| RS (2) | RS58945B1 (pl) |
| RU (1) | RU2583787C2 (pl) |
| SG (1) | SG186140A1 (pl) |
| SI (2) | SI3070091T1 (pl) |
| TR (1) | TR201909709T4 (pl) |
| TW (1) | TWI507410B (pl) |
| UA (1) | UA109140C2 (pl) |
| WO (1) | WO2011160632A1 (pl) |
| ZA (1) | ZA201209031B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104822392B (zh) * | 2012-11-30 | 2017-09-08 | 利奥制药有限公司 | 抑制活化的t‑细胞中il‑22表达的方法 |
| CA2953284A1 (en) * | 2014-06-23 | 2015-12-30 | Leo Pharma A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CA3007432A1 (en) * | 2015-12-18 | 2017-06-22 | Leo Pharma A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| IL271399B (en) * | 2017-06-20 | 2022-07-01 | Leo Pharma As | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| US11384096B2 (en) | 2017-12-15 | 2022-07-12 | UNION therapeutics A/S | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors |
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT3911304T (lt) * | 2019-01-15 | 2023-11-10 | UNION therapeutics A/S | Modifikuoto atpalaidavimo tablečių vaisto formos, kurių sudėtyje yra fosfodiesterazės inhibitorių |
| WO2021016409A1 (en) * | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
| CN112552276B (zh) * | 2019-09-25 | 2023-03-21 | 中国科学院上海药物研究所 | 苯并氧杂卓-5-酮类化合物及其制备方法和用途 |
| WO2022200339A1 (en) | 2021-03-22 | 2022-09-29 | UNION therapeutics A/S | Treatment of hidradenitis suppurativa with orismilast |
| GB202205715D0 (en) | 2022-04-19 | 2022-06-01 | Union Therapeutics As | Treatment of neutrophilic dermatoses |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0706513T1 (en) * | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| GB9507297D0 (en) | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
| AU705690B2 (en) | 1995-05-19 | 1999-05-27 | Kyowa Hakko Kogyo Co. Ltd. | Oxygen-containing heterocyclic compounds |
| NZ332340A (en) * | 1996-05-20 | 2000-04-28 | Darwin Discovery Ltd | 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments |
| CA2272327A1 (en) * | 1996-11-19 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Oxygen-containing heterocyclic compounds |
| JP2005060375A (ja) * | 2003-07-28 | 2005-03-10 | Kyowa Hakko Kogyo Co Ltd | 含酸素複素環化合物 |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1831227B1 (en) * | 2004-12-17 | 2013-06-19 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| CN101631792B (zh) * | 2007-02-28 | 2013-05-01 | 利奥制药有限公司 | 新的磷酸二酯酶抑制剂 |
| KR101571654B1 (ko) * | 2007-02-28 | 2015-11-25 | 레오 파마 에이/에스 | 신규한 포스포디에스테라제 억제제 |
| ES2583478T3 (es) * | 2011-12-21 | 2016-09-21 | Leo Pharma A/S | [1,2,4] triazolopiridinas y su uso como inhibidores de fosfodiesterasa |
-
2011
- 2011-06-24 NZ NZ603895A patent/NZ603895A/en unknown
- 2011-06-24 SI SI201131743T patent/SI3070091T1/sl unknown
- 2011-06-24 HU HUE16020112 patent/HUE044301T2/hu unknown
- 2011-06-24 WO PCT/DK2011/000069 patent/WO2011160632A1/en not_active Ceased
- 2011-06-24 AU AU2011269429A patent/AU2011269429B2/en active Active
- 2011-06-24 LT LTEP16020112.5T patent/LT3070091T/lt unknown
- 2011-06-24 MY MYPI2012005553A patent/MY157481A/en unknown
- 2011-06-24 KR KR1020137001855A patent/KR101864578B1/ko active Active
- 2011-06-24 RU RU2013103079/04A patent/RU2583787C2/ru active
- 2011-06-24 PT PT117298893T patent/PT2585469T/pt unknown
- 2011-06-24 DK DK11729889.3T patent/DK2585469T3/en active
- 2011-06-24 CA CA2802895A patent/CA2802895C/en active Active
- 2011-06-24 RS RS20190851A patent/RS58945B1/sr unknown
- 2011-06-24 LT LTEP11729889.3T patent/LT2585469T/lt unknown
- 2011-06-24 PT PT16020112T patent/PT3070091T/pt unknown
- 2011-06-24 RS RS20160581A patent/RS55104B1/sr unknown
- 2011-06-24 TR TR2019/09709T patent/TR201909709T4/tr unknown
- 2011-06-24 UA UAA201300812A patent/UA109140C2/uk unknown
- 2011-06-24 MX MX2012014131A patent/MX2012014131A/es active IP Right Grant
- 2011-06-24 PL PL11729889T patent/PL2585469T3/pl unknown
- 2011-06-24 CN CN201180031069.5A patent/CN102958937B/zh active Active
- 2011-06-24 ES ES11729889.3T patent/ES2584055T3/es active Active
- 2011-06-24 HU HUE11729889A patent/HUE030081T2/en unknown
- 2011-06-24 US US13/806,659 patent/US8980905B2/en active Active
- 2011-06-24 EP EP11729889.3A patent/EP2585469B1/en active Active
- 2011-06-24 ES ES16020112T patent/ES2733092T3/es active Active
- 2011-06-24 PL PL16020112T patent/PL3070091T3/pl unknown
- 2011-06-24 SG SG2012088761A patent/SG186140A1/en unknown
- 2011-06-24 BR BR112012032813-1A patent/BR112012032813B1/pt active IP Right Grant
- 2011-06-24 SI SI201130896A patent/SI2585469T1/sl unknown
- 2011-06-24 DK DK16020112.5T patent/DK3070091T3/da active
- 2011-06-24 EP EP16020112.5A patent/EP3070091B1/en active Active
- 2011-06-24 HR HRP20160919TT patent/HRP20160919T1/hr unknown
- 2011-06-24 JP JP2013515698A patent/JP6174997B2/ja active Active
- 2011-06-24 TW TW100122303A patent/TWI507410B/zh active
-
2012
- 2012-11-28 IL IL223329A patent/IL223329A/en active IP Right Grant
- 2012-11-29 ZA ZA2012/09031A patent/ZA201209031B/en unknown
-
2014
- 2014-12-30 US US14/586,681 patent/US9273064B2/en active Active
-
2015
- 2015-10-01 US US14/872,487 patent/US9637499B2/en active Active
-
2016
- 2016-03-16 JP JP2016052707A patent/JP2016164168A/ja active Pending
- 2016-07-28 CY CY20161100745T patent/CY1117862T1/el unknown
-
2019
- 2019-06-21 HR HRP20191136TT patent/HRP20191136T1/hr unknown
- 2019-06-28 CY CY20191100679T patent/CY1122201T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295518B1 (en) | Heterocyclic compounds used as pdk1 inhibitors | |
| IL223329A (en) | Benzodioxole or benzodioxoxine heterocyclic compounds as phosphodiesterase inhibitors | |
| IL225770A0 (en) | Heterocyclic compounds | |
| AP2013007252A0 (en) | Heterocyclic compounds as kinase inhibitors | |
| IL221442A0 (en) | Heterocyclic compound | |
| IL218271A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| ZA201300950B (en) | Heterocyclic compound | |
| GB201016880D0 (en) | Phosphodiesterase inhibitors | |
| IL218114A0 (en) | 5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors | |
| ZA201006719B (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| IL223131A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| EP2379538A4 (en) | HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER | |
| IL220205A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| BR112013010643A2 (pt) | compostos heterocíclicos | |
| EP2611806A4 (en) | HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES | |
| BR112013005210A2 (pt) | compostos heterocíclicos como inibidores de dgat1 | |
| IL213935A0 (en) | Novel heterocyclic compounds as metap-2 inhibitors | |
| GB201021416D0 (en) | Novel heterocyclic compounds | |
| GB201009514D0 (en) | Novel heterocyclic compounds | |
| GB0919817D0 (en) | Heterocyclic compounds | |
| GB0919816D0 (en) | Heterocyclic compounds | |
| GB201009730D0 (en) | Kinase inhibitor compounds |